Popular weight loss drugs like Ozempic and Wegovy could deliver measurable economic benefits by significantly reducing employee sick leave, according to an economic study published this month by the National Bureau of Economic Research. The research found that GLP-1 medications resulted in workers taking 17 percent less long-term sick leave, translating to substantial financial savings for employers and public systems alike.
Economic Impact of GLP-1 Medications on Sick Leave
The study examined the connection between GLP-1 drugs and workplace absences using data from Denmark. Researchers defined “long-term” absences as those exceeding 30 days related to illness. According to the findings, the 17 percent reduction in these extended absences translated to savings of up to 1.5 percent of an affected worker’s salary.
Originally developed to treat diabetes, GLP-1 receptor agonists have surged in popularity for weight management. Ongoing medical research continues to evaluate secondary health benefits associated with the medications, including decreased risks of cardiovascular disease and certain types of cancer, which may further influence workforce health trends.
Contrasting Sick Leave Policies: Denmark and the US
According to the study, Denmark maintains particularly generous sick leave regulations compared to the United States. Danish employers are legally required to fund a worker’s full salary for illness-related absences lasting up to 30 days, after which the government assumes responsibility for covering long-term leave past the one-month mark.
Did you know? GLP-1 medications were originally engineered to manage type 2 diabetes before clinical observations revealed their effectiveness in promoting significant weight loss.
Frequently Asked Questions
How do GLP-1 drugs affect workplace absenteeism?
According to National Bureau of Economic Research data, employees taking medications like Ozempic and Wegovy took 17 percent less long-term sick leave.
What defines long-term sick leave in the study?
The research defines long-term sick leave as illness-related absences lasting more than 30 days.
How much financial savings did the reduced sick leave generate?
The decrease in absences resulted in savings amounting to up to 1.5 percent of a worker’s salary.
Stay Informed on Workplace Health Trends
As research into the broader societal and economic impacts of anti-obesity medications evolves, understanding these trends remains essential for employers and policymakers. Explore our workplace health archives for more economic analysis or subscribe to our newsletter for regular updates.
Worth a look